Kei,OGXI up 24% on a solid volume,trading nearly half of it's Cash and there are many upcoming Catalysts:
Based on our current expectations, we believe that our cash, cash equivalents, and short-term investments will be sufficient to
fund our currently planned operations into the first quarter of 2017, which may include:
o
announcing AFFINITY trial results, including final results of the poor prognosis subpopulation by the end of 2015 and
final analysis for the ITT population in the second half of 2016, depending on timing of the event-driven final analysis;
o
announcing ENSPIRIT trial results, which could be available in the second half of 2016;
o
announcing Spruce trial results for the primary PFS endpoint in the first quarter of 2016;
o
announcing Borealis-2 trial results in 2016;
o
completing enrollment in the Pacific trial; and,
o
continuing enrollment in the Spruce-2 trial, formerly referred to as the Cedar Trial
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
